Profound Medical (NASDAQ:PROF – Get Free Report) and Tempest Therapeutics (NASDAQ:TPST – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Profound Medical and Tempest Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
| Tempest Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
Profound Medical currently has a consensus target price of $12.00, indicating a potential upside of 76.21%. Given Profound Medical’s stronger consensus rating and higher probable upside, research analysts clearly believe Profound Medical is more favorable than Tempest Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Profound Medical | -206.76% | -78.88% | -64.06% |
| Tempest Therapeutics | N/A | -355.61% | -121.21% |
Valuation and Earnings
This table compares Profound Medical and Tempest Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profound Medical | $16.10 million | 15.37 | -$42.57 million | ($1.24) | -5.49 |
| Tempest Therapeutics | N/A | N/A | -$26.26 million | ($6.01) | -0.25 |
Tempest Therapeutics has lower revenue, but higher earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Profound Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.75, suggesting that its stock price is 275% less volatile than the S&P 500.
Summary
Profound Medical beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
About Tempest Therapeutics
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.
